Validation of an Ex Vivo Permeation Method for the Intestinal Permeability of Different BCS Drugs and Its Correlation with Caco-2 In Vitro Experiments by Sánchez, Aroha B. et al.
pharmaceutics
Article
Validation of an Ex Vivo Permeation Method for the
Intestinal Permeability of Different BCS Drugs and
Its Correlation with Caco-2 In Vitro Experiments
Aroha B. Sánchez 1, Ana C. Calpena 1 , Mireia Mallandrich 1 and Beatriz Clares 2,*
1 Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and
Food Sciences, University of Barcelona, 08028 Barcelona, Spain; aroha_89_1@hotmail.com (A.B.S.);
anacalpena@ub.edu (A.C.C.); mireia.mallandrich@ub.edu (M.M.)
2 Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Granada,
18071 Granada, Spain
* Correspondence: beatrizclares@ugr.es; Tel.: +34-958246664
Received: 21 October 2019; Accepted: 27 November 2019; Published: 29 November 2019 
Abstract: The absorption study of drugs through different biological membranes constitutes
an essential step in the development of new pharmaceutical dosage forms. Concerning orally
administered forms, methods based on monolayer cell culture of Caco-2 (Caucasian colon
adenocarcinoma) have been developed to emulate intestinal mucosa in permeability studies. Although
it is widely accepted, it has disadvantages, such as high costs or high technical complexity, and
limitations related to the simplified structure of the monolayer or the class of molecules that can be
permeated according to the transport mechanisms. The aim of this work was to develop a new ex vivo
methodology which allows the evaluation of the intestinal apparent permeability coefficient (Papp)
while using fewer resources and to assess the correlation with Caco-2. To this end, pig (Sus scrofa)
duodenum segments were mounted in Franz diffusion cells and used to permeate four different drugs:
ketorolac tromethamine (Kt), melatonin (Mel), hydrochlorothiazide (Htz), and furosemide (Fur).
No statistically significant differences (p > 0.05) were observed corelating Papp values from Franz
diffusion cells and Caco-2 cell experiments for Kt, Htz, and Fur. However, there were statistically
significant differences (p < 0.05) correlating Papp values and Mel. The difference is explained by the
role of Mel in the duodenal epithelial paracellular permeability reduction. Ex vivo permeation may
be an equivalent method to Caco-2 for drugs that do not produce intestinal membrane phenomena
that could affect absorption.
Keywords: Franz cells; Caco-2 cells; intestinal permeability; apparent permeability coefficient
1. Introduction
At the earliest stages of drug product or new pharmaceutical dosage form development, in vitro
permeation through Caco-2 (human epithelial colorectal adenocarcinoma cell monolayer line) is widely
accepted to estimate the intestinal apparent permeability coefficient (Papp). As described in Figure 1,
Caco-2 is a donor–receptor compartment apparatus separated by a cell monolayer grown on a porous
polycarbonate filter. Papp, defined as the flux of a substance permeating a membrane from the donor to
receptor compartment normalized by the membrane surface and initial concentration in the donor
chamber [1], is usually obtained based on a two-compartmental model approach; however, some
authors have developed an alternative definition of a Papp index for three-compartment models
describing the membrane as well as donor and receiver compartments [2]. This index may be predictive
of oral bioavailability, showing an acceptable correlation with a human one, especially for drugs
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absorbed by passive diffusion. Carrier-mediated absorption drugs are not so easily extrapolated
and require a scaling factor because of the low expression of carriers in this cell line [3]. Both
undifferentiated and differentiated Caco-2 models have been developed, with the undifferentiated
being more susceptible than the differentiated and, therefore, effective in cytotoxicity and cytoprotective
studies [4–8]. More complex differentiated models are suitable for studying transport mechanisms and
efficacy of substances [9–12].
Figure 1. Caco-2 diagram formed by a transwell insert preloaded with polycarbonate membrane inserts
with a known pore size. Original figure drawn in Edraw Max 9.4.
Focusing on the relevance of Caco-2 in the design, optimization, and selection of potential
candidates in the development of oral drugs, cell monolayer lines have been used for the study of
improving the oral absorption of highly lipophilic and poorly water-soluble drugs [13]; lipid-based
self-emulsifying drug delivery systems [14]; and for the evaluation of new oral formulations based on
nanotechnology, such as solid lipid nanoparticles (SLNps) [15], or bioadhesive drug delivery systems,
such as chitosan-modified nanoparticles [10]. Caco-2 has been optimized, although it exhibits variability
attributable to biological methods [16], and the significance of emulating physiological conditions
to improve in vitro experiments, for example, using bile acids, surfactants, or plasma proteins, is
well known for providing a better in vitro–in vivo correlation [17]. Because of their usefulness and
relevance, international institutions such the FDA accept in vitro permeability studies across Caco-2
to classify the permeability of drug substances according to the Biopharmaceutics Classification
System (BCS) proposed in the International Council for Harmonization of Technical Requirements for
Pharmaceuticals for Human Use (ICH) guidelines [18].
Regardless of it being an established method, the Caco-2 cell model has some disadvantages,
such as its high cost or the need for highly specialized staff, which can be restrictive in both academic
and private sector environments, where the optimization of resources is a paramount task. Other
limitations are related to the structural and functional differences between a monolayer of cells and
a biological membrane, such as the intestinal one. In contrast to Caco-2, which is a monolayer of
cells, the gastrointestinal (GI) tract is composed of four main layers: tunica mucosa (mucous layer),
tunica submucosa (submucous layer), tunica muscularis (muscle layer), and tunica serosa (serous
layer) (Figure 2), which are additionally composed of different layers. Tunica mucosa is the most
proximal layer to the lumen, which contains a thick layer of mucous covering the epithelial cells that
are linked together by intercellular linkages, and an underlying layer called the lamina propria. The
small intestine epithelium is a simple columnar epithelium, typical of regions of high secretion and
absorption functions. The cells of simple columnar epithelium form finger-like projections called villi.
In addition to intestinal villi, the surface of the cells contains microvilli, which collectively increase the
surface area of the lumen by 400–600-fold [19].
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Figure 2. (a) Basic structure of small intestine layers, (b) a simplified schematic representation of villi,
and (c) epithelium composed of intestinal epithelial cells including types of intercellular junctions.
Original figure drawn from Edraw Max 9.4.
Other important features of GI epithelium are the structural linkages between cells that connect
the plasma membrane of neighboring cells. Four classes of intercellular junctions have been described:
gap junctions (selective for small molecules such as ions, second messengers, and metabolites), tight
junctions (paracellular barrier regulating the movement of water and solutes between epithelial layers),
adherens junctions (help to seal the space between cells), and desmosomes (help to maintain shear
forces and mechanical stress) (Figure 2c) [19].
GI membrane complexity demonstrates that drug absorption across this barrier is a multipathway
process which could be classified as transcellular and paracellular. The most important is the
transcellular route, whereby compounds go across the cells by traversing the cell membrane following
passive diffusion or carrier-mediated transport (active transport, facilitated diffusion, absorption
limited by P-glycoprotein or other efflux transports, intestinal first-pass metabolism followed by
absorption of parent and metabolite- and receptor-mediated transport). There is also a paracellular
passive diffusion via the junction route [20].
As explained above, the use of Caco-2, although predictive, is a very simplified approach to the GI
membrane, so the use of ex vivo methods may lead to more accurate predictions of Papp. Nejdfors et al.
studied the permeability of C-mannitol, fluorescein isothiocyanate (FITC)–dextran 4400, a-lactalbumin,
ovalbumin, and FITC–dextran through different intestinal regions of humans, rats, and pigs using
small diffusion chambers of 5 mL and 1.74 cm2 of exposed tissue area (Navicyte, San Diego, CA,
USA) [21]. Differences between intestinal regions and species were detected, and a good correlation
between humans and pigs was also observed, mainly for the polyol mannitol in the jejunum and ileum.
Papp was not compared with Caco-2 values, but the experiment showed that the use of intestinal
membranes may be predictive of oral bioavailability.
Considering all the above, the aim of this work was to develop an alternative technique to Caco-2
and small diffusion cells, which allows the evaluation of the intestinal absorption rate or Papp for
different drugs while using fewer resources and to assess the correlation with Caco-2. The purpose was
Pharmaceutics 2019, 11, 638 4 of 12
to provide a new suitable and economical ex vivo method to test and compare new oral formulations
or modified release systems, including therapeutic and higher drug concentrations than Caco-2.
2. Materials and Methods
2.1. Chemical and Reagents
Melatonin (Mel), ketorolac tromethamine (Kt), hydrochlorothiazide (Htz), ammonium dihydrogen
phosphate (NH4H2PO4), phosphoric acid (H3PO4), disodium hydrogen phosphate (Na2HPO4), and
tetrahydrofuran (THF) were purchased from Sigma-Aldrich (Madrid, Spain). Furosemide (Fur) was
supplied by Acofarma (Barcelona, Spain). Potassium dihydrogen phosphate (KH2PO4), potassium
hydroxide (KOH), acetonitrile (ACN), and methanol (MeOH) were purchased from Panreac Quimica
(Barcelona, Spain). Hanks’ balanced salt solution (HBSS) was purchased from Merck S.L. (Barcelona,
Spain). Double-distilled water was obtained from a Milli-Q® Gradient A10 system apparatus (Millipore
Iberica S.A.U., Madrid, Spain).
2.2. Instrumentation
HPLC-UV Procedure
The HPLC equipment consisted of a Waters® Alliance 2695 Separation Module (Waters Co.,
Milford, MA, USA) with a 2996 Photodiode Array Detector (DAD) at a wavelength range of 190–800 nm
and sensitivity settings from 0.0001 to 2.0000 absorbance units. HPLC parameters are summarized in
Table 1 and listed below.
Table 1. Summary of HPLC parameters for ketorolac tromethamine (Kt), melatonin (Mel), furosemide




ʎ (nm) Mobil Phase Flow Rate(mL/min) IV
2 (µL)
Kt C8, 150 × 2.1 mm, 5 µm 313 NH4H2PO:THF (70:30) 0.25 100
Mel C18, 100 × 4.6 mm, 3.5 µm 223 H2O:MeOH (55:45) 0.60 100
Fur C18, 150 × 3.9 mm, 4 µm 230 KH2PO4:CAN (80:20) 0.50 100
Htz 100 ODS2, 100 × 4.6, 3 µm 224 NaH2PO4:MeOH:THF1 0.70 100
1 Hydrochlorothiazide HPLC mobile phase consisted of a gradient elution of two solutions: A (93:6:1) and B
(47.6:47.6:4.8). 2 IV: injection volume.
Kt analysis was conducted with a reverse-phase column C8 (150 × 2.1 mm) packed up with 5 µm
(Kromasil®, Teknokroma Anlítica, SA; Barcelona, Spain), with a UV detector set up at 313 nm. The
mobile phase, previously filtered by a 0.45 µm nylon membrane filter (Technokroma, Barcelona, Spain)
and degassed by sonication, consisted of a 70:30 ratio of NH4H2PO (5.75 g/L; pH 3) to THF under
isocratic elution at a flow rate of 0.25 mL/min. The injection volume was 10 µL.
Mel analysis was performed with a reverse-phase column C18 (150 × 4.6 mm) packed up with
3.5 µm (SunFire®, Waters Co., Milford, MA, USA), with a UV detector set up at 223 nm. The
mobile phase, previously filtered by a 0.45 µm nylon membrane filter (Technokroma and degassed by
sonication, consisted of a 55:45 ratio of double-distilled water to MeOH under isocratic elution at a
flow rate of 0.6 mL/min. The injection volume was 100 µL.
Fur analysis was carried out with a reverse-phase column C18 (150 × 3.9 mm) packed up with
4 µm (Nova-Pack®, Waters Co., Milford, MA, USA), with a UV detector set up at 230 nm. The mobile
phase, previously filtered by a 0.45 µm nylon membrane filter (Technokroma, Barcelona, Spain) and
degassed by sonication, consisted of an 80:20 ratio of KH2PO4 (0.01M; pH of 6.3, adjusted with KOH
10%) to ACN under isocratic elution at a flow rate of 0.5 mL/min. The injection volume was 100 µL.
Htz analysis was conducted with a reverse-phase column ultrabase 100 ODS2 analytical column
(100 × 4.6 nm; diameter of 3 µm (Akady, Spain)) with a UV detector set up at 224 nm. The mobile
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phase, previously filtered by a 0.45 µm nylon membrane filter (Technokroma, Barcelona, Spain) and
degassed by sonication, consisted of a gradient elution of two solutions (A and B) at a flow rate of
0.7 mL/min. Solution A consisted of 940 mL of NaH2PO4 (35.8 g/L; pH of 3.2, adjusted with H3PO4)
with 60 mL of MeOH and 10 mL of THF. Solution B consisted of 500 mL of NaH2PO4 (35.8 g/L; pH of
3.2, adjusted with H3PO4) with 500 mL of MeOH and 50 mL of THF. The percentage of B was 20% at
time 0, 20% at 4 min, 80% at 10 min, 80% at 12 min, 20% at 13 min, and 20% at 20 min. The injection
volume was 100 µL.
2.3. Validation and Verification of Analytical Methods
Previously validated HPLC-UV methods were selected for the analysis of the four assayed analytes.
Considering that the samples were obtained from biological sources, the specificity was studied.
Specificity, expressed by the ICH guidelines as the ability to assess an analyte in the presence of
components which may be expected to be present, was evaluated by the absence of interference of the
phosphate-buffered saline (PBS; pH 7.4) and other components from biological membranes used as a
blank at the retention times shown by the different standard solutions.
2.4. Ex Vivo Permeation Studies through Pig Intestine
2.4.1. Franz Cell System and Intestinal Membrane
Ex vivo permeation was performed in the duodenum, the most proximal portion of the small
intestine, of young female pigs (Sus scrofa). Animals were sacrificed for other purposes in the Animal
Facility at Bellvitge Campus (University of Barcelona, Spain) (no. 7428) (Date of approval: 10
January 2019), and intestinal samples were obtained according to the 3R (reduction, refinement and
replacement) principle.
The duodenum was excised, cleaned, and preserved in HBBS at 5 ± 3 ◦C for 12 h. Then, 6 × 6 cm
pieces were cut, mounted on the metal ring of the Franz cells as shown in Figure 3, and the remaining
corners were trimmed.
Figure 3. Piece of proximal small intestine of young female pigs (Sus scrofa) mounted on the metal ring
of the Franz cells.
To avoid damage to the biological intestinal membrane, 0.02 M PBS (pH 7.4) was prepared as
a receiving medium. The composition was 0.6 g of KH2PO4 and 3.17 g of Na2HPO4 per liter of
double-distilled water. The pH value was adjusted with H3PO4 or NaOH.
The ex vivo permeation study was performed in Franz diffusion cells (Vidra Foc Barcelona, Spain),
where duodenum portions were placed between the receptor and donor compartments with the basal
side in contact with the receiving medium and the apical side in contact with the donor chamber,
avoiding bubble formation. The diffusion area was 2.54 cm2. A representative chart of the Franz cell
system is shown in Figure 4.
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Figure 4. Franz cell scheme (a), including permeation membrane model (b) formed by the proximal
small intestine of young female pigs (S. scrofa) that were opened with an incision and positioned with
the area corresponding to the microvilli of the enterocytes in contact with the donor compartment and
the basolateral part in contact with the receptor compartment. Original figure drawn in Edraw Max 9.4.
Homogeneity during experiments was ensured by a small Teflon®-coated magnetic stir bar at
700 rpm. The diffusion cells were previously incubated in a water bath to equalize the temperature in
all cells (37 ± 1 ◦C).
2.4.2. Donor Solution Preparation and Sampling Method
Four drugs according to BCS classification were randomly selected. Table 2 includes the chemical
structure; pKa (negative base 10 logarithm of the acid dissociation constant (Ka) of a solution) values;
and tested formulations, including solvents, drug concentration, and pH.
Table 2. Name, structure, Biopharmaceutics Classification System (BCS) type, and pKa (negative
base 10 logarithm of the acid dissociation constant (Ka) of a solution) of selected drugs for
permeation experiments.
Molecule Structure BCS pKa Dissolution Media Concentration
Ketorolac
tromethamine Class 1 3.5 [22] PBS pH 7.4 1 mg/mL
Melatonin Class 2 16.5 [23] PBS pH 7.4 0.8 mg/mL
Hydrochlorothiazide Class 3 7.9 [24] PBS pH 7.4 0.05 mg/mL
Furosemide Class 4 3.9 [25] PBS pH 7.4 0.6 mg/mL
All the drugs were dissolved by stirring at 30 ± 0.1 ◦C in PBS (pH 7.4) to guarantee the
biocompatibility to the permeation membrane. Infinite dose conditions were ensured in all experiments.
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The donor compartment was then sealed by parafilm to prevent water evaporation. All the
experiments were carried out under sink conditions, ensuring that the drug concentration in the
receptor compartment was negligible compared to the donor one.
Samples of 300 µL were collected via a sampling port from the middle of the receptor compartment
at preselected time intervals (30, 60, 90, 120, 180, 240, 300, 360, and 420 min) for 7 h. The removed
sample volume was immediately replaced with the same volume of tempered fresh receiving medium
of each molecule with great care to avoid trapping air beneath the membrane.
2.4.3. Sample Analysis
The cumulative amount of the different BCS drugs through the small intestine membrane from
the acceptor compartment was monitored by a validated HPLC-UV methodology. Results are reported
as mean ± SD of five experiments for each drug.
2.4.4. Data Treatment and Statistical Analysis
Our permeability model has the same structure as the two-compartment classic model, composed
of donor (apical) and receptor (basal) chambers, both separated by the permeation membrane. So,
apical-to-basal Papp was calculated based on classic parameters according to Equation (1):
Papp = (dQ/dt) / (C0 x A) (1)
where (dQ/dt) is the transport rate or flux (J) (µg/min) across the biological membrane, C0 (µg/mL)
is the initial concentration of the drug in the donor chamber, and A is the surface area (cm2) of the
permeation membrane.
The cumulative amount (Q) (µg) permeated through porcine duodenum was obtained by
multiplying the acquired concentration (µg/mL) of each drug at the receptor chamber and the volume
(mL) of the receptor chamber. J (µg/min) was calculated as the slope at the steady state obtained by
linear regression analysis (GraphPad Prism® software, v. 5.01, GraphPad Software Inc., San Diego,
CA, USA) of Q as a function of time (min). Then, Papp (cm/min) was calculated according to Equation
(1) by dividing the J (µg/min), the permeation area (A) (2.54 cm2), and the initial drug concentration
(C0) (µg/mL = µg/cm3) in the donor chamber. Finally, the units were expressed in centimeters per
second for comparison with the obtained results in the Caco-2 experiments. It was assumed that under
sink conditions, the drug concentration in the receptor compartment is negligible compared to the
donor compartment.
Obtained experimental data were analyzed by unpaired Student’s t-test to compare Papp values
for both bibliographic Caco-2 results and experimental data obtained with Franz cells. A p-value < 0.05
was established as an indicator of statistically significant differences.
3. Results and Discussion
3.1. Obtained Kinetics Parameters and Papp Calculation
Table 3 shows the kinetics parameters of Kt, Mel, Fur, and Htz. Cumulative permeated drug was
measured. Then, the flux and flux normalized by the permeation area (2.54 cm2) were calculated.
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Table 3. Permeation parameters for Kt, Mel, Fur, and Htz solutions in vertical Franz cells (n = 5).
Permeation Parameters Kt Mel Htz Fur
Flux (µg/min) 0.855 ± 0.069 0.683 ± 0.016 0.004 ± 0.0002 0.0180 ± 0.0018
Flux/sup (µg/(cm/min)) 0.336 ± 0.027 0.268 ± 0.006 0.0015 ± 0.0001 0.0071 ± 0.0001
Co (µg/mL) 1000 800 50 600
Papp (x10−6) (cm/s) 5.609 ± 0.452 5.598 ± 0.130 0.487 ± 0.026 0.196 ± 0.020
Abbreviation: Papp—apparent permeability coefficient.
Figure 5 shows Kt, Mel, Htz, and Fur cumulative permeated amounts in micrograms as a function
of time (min).
Figure 5. Cumulative permeated amounts (µg) as a function of time (min) of ketorolac tromethamine
(a), melatonin (b), furosemide (c), and hydrochlorothiazide (d). Results are reported as mean ± SD
(n = 5).
3.2. Specificity
Under the assay conditions described in the methodology section for each analyte, the mean
retention times of Kt, Fur, Mel, and Htz were 9.45, 3.03, 5.05, and 9.5 min, respectively. The selectivity
of the selected analytical method was confirmed by the studied chromatograms (Table S1), where
Kt, Fur, Mel, and Htz peaks did not overlap with any other of the endogenous components of the
medium. Blanks were obtained at time T0, from the receptor compartment, after incubation of diffusion
cells and before adding the drugs. Therefore, the method is considered specific for the detection and
quantification of the four molecules.
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3.3. Correlation between Papp in Caco-2 versus Franz Cells
After a literature search, different Caco-2 permeation studies and Papp values were found for the
tested drugs, which are summarized in Table 4.
Table 4. Papp values expressed as mean ± SD (cm/s) from different literature datasets about Kt, Mel,
Fur, and Htz in Caco-2 experiments.
Drug Papp (×10−6) (cm/s) (AP→ BL)) Caco-2 Cells
Kt 8.30 ± 5.20 (n = 6) (HBBS1 pH 7.4) [26]
Mel 12.50 ± 0.01 (n = 3) (HEPES2 pH 7.4) [27]
Htz 0.51 ± 0.02 (n = 3) (HBBS1 pH 7.4) [28]
Fur 0.19 ± 0.01 (n = 3) (KBR3 pH 7.4) [29]
1 Hank’s balanced salts solution; 2 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; 3 Krebs–Ringer modified
buffer (KBR).
Table 5 shows that no statistically significant differences (p > 0.05) were observed correlating
Franz diffusion cells and Caco-2 cell experiments Papp values for Kt, Htz, and Fur. However, there
were statistically significant differences (p < 0.05) correlating Papp values for Mel. Figure 6 shows a plot
of statistical correlation.
Table 5. Statistical correlation between both Franz diffusion cells and Caco-2 experiments. Papp values
are expressed as mean ± SD (cm/s) for Kt, Mel, Fur, and Htz.
Drug
Papp (×10−6) (cm/s) (AP→ BL)
Franz Diffusion Cells (PBS pH 7.4) Caco-2 (pH 7.4) 1 Unpaired t-Test (p)
Kt 5.61 ± 0.45 (n = 5) 8.3 ± 5.2 (n = 6) [26] 0.28 (p > 0.05)
Mel 5.60 ± 0.13 (n = 5) 12.50 ± 0.01 (n = 3) [27] 0.0001 (p < 0.05) *
Htz 0.49 ± 0.03 (n = 5) 0.42 ± 0.33 (n = 3) [28] 0.30 (p > 0.05)
Fur 0.20 ± 0.020 (n = 5) 0.19 ± 0.01 (n = 3) [29] 0.87 (p > 0.05)
1 Caco-2 experiments were carried out in Hank’s balanced salts solution (pH 7.4) for Kt and Htz, HEPES (pH 7.4) for
Mel, and KBR pH 7.4 for Fur.
Figure 6. Comparative Papp between both Franz diffusion cells and Caco-2 cell culture for Kt, Mel, Htz,
and Fur. Data are expressed as mean ± SD × 10−6 (cm/s). * p < 0.05.
Papp statistical correlation for both Franz diffusion cells and Caco-2 cell culture indicates that the
ex vivo permeation is an equivalent method to Caco-2 for Kt, Htz, and Fur, which are BCS classes 1, 3,
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and 4, respectively. Regarding Mel, the obtained Franz diffusion cell Papp values showed statistically
significant differences, with the ex vivo permeation data being 1.79 times lower than Caco-2. This
could be related to the intestinal accumulation of Mel described in mammals [30], where Mel intestinal
receptors MT1 and MT2 are involved in multiple roles, such as regulation of gastrointestinal motility
and epithelial permeability [31]. It could also be explained by the fact that Mel, although it exhibits
protein-facilitated transport [32], reduces the duodenal epithelial paracellular permeability [33]. This
may justify the Papp value of 2.31 ± 0.12 × 10−6 cm/s (n = 4) for Mel obtained by other authors in an
ex vivo permeation through rat jejunum in small diffusion chambers [34], which is also a lower and
statistically different value than Caco-2. The difference may be also associated with the cytotoxicity in
Caco-2 promoted by Mel concentrations of 1.56 and 0.78 µg/mL [35]. The ultrastructural damage in a
simple structure such as a monolayer of cells would increase permeability through tight junctions,
leading to an increased Papp value. Both circumstances would explain the differences. Drug solubility
is not a limiting factor when applying Franz diffusion cells through an intestinal ex vivo membrane
since Fur, which is BCS class 4, shows a good correlation. In contrast, intestinal membrane phenomena
that modify intestinal permeation, such as accumulation or metabolism (among others), may hinder
this method in the case of Mel.
4. Conclusions
A new ex vivo technique based on permeation through pig small intestinal membrane was
developed. It allows the prediction of absorption rate or Papp and apical-to-basal permeation for
different BCS drugs. This ex vivo method requires fewer economic resources than other in vitro
techniques for Papp determination, providing a new suitable process to test and compare new oral
formulations or modified release systems, including therapeutic and higher drug concentrations than
Caco-2. Application of this method requires determining if the drug produces intestinal membrane
phenomena that could affect the absorption process.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4923/11/12/638/s1,
Table S1: HPLC-UV chromatograms of blank vs. standard solutions of ketorolac, furosemide, melatonin and Htz.
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